| 英文名稱 | Elacestrant (Synonyms: RAD1901) |
|---|---|
| 中文名稱 | (R)-6-(2-(乙基(4-(2-(乙基氨基)乙基)芐基)氨基)-4-甲氧基苯基)-5,6,7,8-四氫萘-2-醇;艾拉司群 |
| CAS號 | 722533-56-4 |
| 分子式 | C30H38N2O2 |
| 分子量 | 458.63 |
| MDL | MFCD30532693 |
| 外觀 | White to off-white powder |
| 儲存條件 | 4°C, sealed storage, away from moisture and light |
| 英文名稱 | Elacestrant (Synonyms: RAD1901) |
|---|---|
| 中文名稱 | (R)-6-(2-(乙基(4-(2-(乙基氨基)乙基)芐基)氨基)-4-甲氧基苯基)-5,6,7,8-四氫萘-2-醇;艾拉司群 |
| CAS號 | 722533-56-4 |
| 分子式 | C30H38N2O2 |
| 分子量 | 458.63 |
| MDL | MFCD30532693 |
| 外觀 | White to off-white powder |
| 儲存條件 | 4°C, sealed storage, away from moisture and light |
Elacestrant (RAD1901) is a potent oral SERD with IC50s of 48 nM for ERα and 870 nM for ERβ. It effectively inhibits the growth of ER+ breast cancer cell lines both in vitro and in vivo, showcasing its significant bioactivity in targeting estrogen receptor pathways crucial for cancer cell proliferation.
PMID: 26164151 PMCID: PMC4560273 DOI: 10.1097/CAD.0000000000000271
PMID: 28473534 DOI: 10.1158/1078-0432.CCR-16-2561